Antimicrobial resistance in tuberculosis: An international perspective

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 759-766

  van Helden, Paul D ^a   Donald, Peter R ^b   Victor, Thomas C ^a   Schaaf, H Simon ^b   Hoal, Eileen G ^a   Walzl, Gerhard ^a   Warren, Robin M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Drug resistance; Drug trials; Ethambutol; First line; Isoniazid; Rifampicin; Second line; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; EPIDEMIC; HEALTH CARE COST; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; RECURRENCE RISK; SHORT COURSE THERAPY; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 33845465912     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.5.759     Document Type: Article

References (41)

1. Mitchison DA. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis; results of simultaneous sensitivity tests in liquid and on solid media. Thorax 5(2), 144-161 (1950).
2. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 20(5), 810-814 (1970).
3. Watterson SA, Wilson SM, Yates MD, Drobniewski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 36(7), 1969-1973 (1998).
4. Streicher EM, Warren RM, Kewley C et al. Genotypic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa. J. Clin. Microbiol, 42(2), 891-894 (2004).
5. Victor TC, Lee H, Cho SN et al. Molecular detection of early appearance of drug resistance during Mycobacterium tuberculosis infection. Clin. Chem. Lab. Med. 40(9), 876-881 (2002).
6. van Rie A, Warren R, Mshanga I et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J. Clin. Microbiol. 39(2), 636-641 (2001).
7. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2(1), 10-15 (1998).
8. Dooley SW, Simone PM. The extent and management of drug-resistant tuberculosis: the American experience. Clinical tuberculosis Chapman & Hall, London, UK 171-189 (1994).
9. Farmer P, Walton D. The social impact of multi-drug-resistant tuberculosis: Haiti and Peru. In: The Return of the White Plague. Gandy M, Zumla A (Eds). Verso, London, UK 163-177 (2003).
10. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283(19), 2537-2545 (2000).
11. Weyer K, Kleeberg HH. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement. Tuber. Lung Dis. 73(2), 106-112 (1992).
12. Kim SJ, Bai GH, Hong YP, Drug-resistant tuberculosis in Korea, 1994. Int. J. Tuberc. Lung Dis. 1(4), 302-308 (1997).
13. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2(5), 489-493 (1999).
14. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48(4), 1289-1294 (2004).
15. Streicher EM, Warren RM, Kewley C et al. Genotypic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa. J. Clin. Microbiol. 42(2), 891-894 (2004).
16. Espinal MA. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int. J. Tuberc. Lung Dis. 7(7), 607-608 (2003).
17. Deriemer K, Garcia-Garcia L, Bobadilla-del-Valle M et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365 (9466), 1239-1245 (2005).
18. Suarez PG, Floyd K, Portocarrero J et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359(9322), 1980-1989 (2002).
19. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int. J. Tuberc. Lung Dis. 8(5), 560-567 (2004).
20. Tinne JE, Henderson JL. Primary streptomycin-resistant tuberculosis in a newborn child. Simple method of assessing streptomycin resistance. Lancet 2(27), 901-904 (1950).
21. Zitrin CM, Lincoln EM. Initial tuberculous infection due to drug-resistant organisms. With a review of the world literature on initial infection due to isoniazid-resistant tubercle bacilli. J. Pediatr. 58, 219-225 (1961).
22. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of M. tuberculosis to rifampin. Am. Rev. Respir. Dis. 134(3), 446-448 (1986).
23. Schaaf HS, Vermeulen HA, Gie RP, Beyers N, Donald PR. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatr. Infect. Dis. J. 18(6), 494-500 (1999).
24. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109(5), 765-771 (2002).
25. van Rie A, Warren R, Richardson M et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341 (16), 1174-1179 (1999).
26. Verver S, Warren RM, Beyers N et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 171 (12), 1430-1435 (2005).
27. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001).
28. Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr. Pharm. Des. 10(26), 3285-3295 (2004).
29. Moore DA, Mendoza D, Gilman RH et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J. Clin. Microbiol. 42(10), 4432-4437 (2004).
30. Victor TC, van Helden PD, Warren R. Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life 53(4-5), 231-237 (2002).
31. Johnson R, Jordaan AM, Pretorius L et al. Ethambutol resistance testing by mutation detection. Int. J. Tuberc. Lung Dis. 10(1), 68-73 (2006).
32. Louw GE, Warren RM, Donald PR et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10(7), 802-807 2006).
33. van Rie A, Warren R, Richardson M et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 356(9223), 22-25 (2000).
34. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation on disease emergence. Nature 438(7066), 355-359 (2005).
35. Park H, Song EJ, Song ES et al. Comparison of a conventional antimicrobial susceptibility assay to an oligonucleotide chip system for detection of drug resistance in Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 44(5), 1619-1624 (2006).
36. Vernet G, Jay C, Rodrigue M, Troesch A. Species differentiation and antibiotic susceptibility testing with DNA microarrays. J. Appl. Microbiol. 96(1), 59-68 (2004).
37. Watterson SA, Wilson SM, Yates MD, Drobniewski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 36(7), 1969-1973 (1998).
38. van Rie A, Warren R, Mshanga I et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J. Clin. Microbiol. 39(2), 636-641 (2001).
39. Maher D, Raviglione M. Global epidemiology of tuberculosis. Clin. Chest Med. 26(2), 167-182 (2005).
40. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 10(10), 1117-1121 (2004).
41. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 10(10), 1111-1116 (2004).